21:47 , Nov 2, 2016 |  BC Innovations  |  Distillery Techniques

Other

TECHNOLOGY: Computational models A computational model for predicting how mutations alter activity could aid the design of therapies that overcome drug resistance. For any protein-compound pair, the model utilizes molecular dynamic simulations to build a...
07:00 , Apr 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer CD248 endosialin (TEM1) Mouse studies suggest a DNA plasmid encoding a TEM1-tetanus toxoid (TT) fusion peptide could be used as a cancer vaccine. TEM1...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

MORAb-004: Phase I started

Eisai's Morphotek Inc. subsidiary said the Children's Oncology Group began an open-label, U.S. Phase I trial to evaluate IV MORAb-004 once weekly in about 65 pediatric patients with recurrent or refractory solid tumors. Morphotek has...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

MORAb-004: Phase II started

Eisai disclosed in its 1Q12 earnings ending June 30 that it began a double-blind, placebo-controlled international Phase II trial to evaluate MORAb-004 in combination with gemcitabine and docetaxel in about 200 patients with metastatic soft...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

MORAb-004: Additional Phase I data

Additional data from a dose-escalation, open-label, U.S. Phase I trial in 36 patients with refractory solid tumors showed that once-weekly 0.0625-16 mg/kg IV MORAb-004 produced 4 minor or mixed tumor responses, and 18 cases of...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

MORAb-004: Phase II started

Eisai's Morphotek Inc. subsidiary began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 8 mg/kg IV MORAb-004 once weekly plus best supportive care in up to 160 patients with refractory mCRC. Morphotek has exclusive,...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

MORAb-004 regulatory update

FDA granted Orphan Drug designation for MORAb-004 from Eisai's Morphotek Inc. subsidiary to treat soft tissue sarcoma (STS). The humanized IgG mAb against CD248 endosialin (TEM1) is in Phase I testing for cancers, including STS....
07:00 , Jun 6, 2011 |  BC Week In Review  |  Clinical News

MORAb-004: Phase II started

Eisai's Morphotek Inc. subsidiary began an open-label, international Phase II trial to evaluate 2 or 4 mg/kg IV MORAb-004 in up to 80 patients. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan   Product: MORAb-004  ...
07:00 , May 30, 2011 |  BC Week In Review  |  Clinical News

MORAb-004: Phase I data

An ongoing, dose-escalation, open-label, U.S. Phase I trial in 23 patients with refractory solid tumors showed that IV MORAb-004 produced 3 minor responses, plus 5 cases of durable stable disease for >8 weeks. Median progression-free...